Witnessing the stock’s movement on the chart, on Thursday, Tourmaline Bio Inc (NASDAQ: TRML) set off with pace as it heaved 10.26% to $16.01, before settling in for the price of $14.52 at the close. Taking a more long-term approach, TRML posted a 52-week range of $11.56-$29.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 0.00%. Meanwhile, its Annual Earning per share during the time was 8.04%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -19.07%. This publicly-traded company’s shares outstanding now amounts to $25.69 million, simultaneously with a float of $16.04 million. The organization now has a market capitalization sitting at $411.22 million. At the time of writing, stock’s 50-day Moving Average stood at $14.42, while the 200-day Moving Average is $19.02.
Tourmaline Bio Inc (TRML) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Tourmaline Bio Inc’s current insider ownership accounts for 37.56%, in contrast to 68.38% institutional ownership. According to the most recent insider trade that took place on Aug 21 ’24, this organization’s CEO bought 1,779 shares at the rate of 14.85, making the entire transaction reach 26,418 in total value, affecting insider ownership by 7,000. Preceding that transaction, on Aug 16 ’24, Company’s CEO bought 5,221 for 13.79, making the whole transaction’s value amount to 71,998. This particular insider is now the holder of 5,221 in total.
Tourmaline Bio Inc (TRML) Earnings and Revenue Records
Tourmaline Bio Inc’s EPS decrease for this current 12-month fiscal period is -19.07% and is forecasted to reach -4.16 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -18.85% through the next 5 years, which can be compared against the 8.04% growth it accomplished over the previous five years trading on the market.
Tourmaline Bio Inc (NASDAQ: TRML) Trading Performance Indicators
Let’s observe the current performance indicators for Tourmaline Bio Inc (TRML). It’s Quick Ratio in the last reported quarter now stands at 40.33. The Stock has managed to achieve an average true range (ATR) of 1.19.
In the same vein, TRML’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.88, a figure that is expected to reach -0.91 in the next quarter, and analysts are predicting that it will be -4.16 at the market close of one year from today.
Technical Analysis of Tourmaline Bio Inc (TRML)
Going through the that latest performance of [Tourmaline Bio Inc, TRML]. Its last 5-days volume of 0.32 million was inferior to the volume of 0.32 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 89.63% While, its Average True Range was 1.23.
Raw Stochastic average of Tourmaline Bio Inc (TRML) in the period of the previous 100 days is set at 29.24%, which indicates a major fall in contrast to 95.49% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 90.03% that was higher than 68.19% volatility it exhibited in the past 100-days period.
